I thought the second point in the summary of the AGM Presentation is an intetesting one.
• HIV‐1/BIT225• BIT225‐009 Phase 2 trial provides clear clinical evidence that BIT225 is having a unique effect inindividuals infected with HIV‐1
• Engaged with the right potential partners, with the right legal/commercial deal‐making skills in place
• This is not a fast process; but we are focused an achieving a commercial outcome
• Preclinical Programs
• HBV has promise as a preclinical candidate for joint development.
• BIT225 results validate the platform; potential to facilitate funded developments by partners for“other” viral diseases
• Regional Licensing
• HCV in China remains a significant development opportunity – “cost‐conscious” market combinedwith the high rate of co‐infection HCV & HBV requires different approach than used in the USA
- Forums
- ASX - By Stock
- updates about the deals
I thought the second point in the summary of the AGM...
-
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
Add BIT (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.9¢ |
Change
-0.001(5.00%) |
Mkt cap ! $17.14M |
Open | High | Low | Value | Volume |
1.9¢ | 1.9¢ | 1.9¢ | $5.671K | 298.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 512798 | 1.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.0¢ | 1050263 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 512798 | 0.019 |
10 | 1774771 | 0.018 |
8 | 927388 | 0.017 |
12 | 3258350 | 0.016 |
10 | 1205000 | 0.015 |
Price($) | Vol. | No. |
---|---|---|
0.020 | 1050263 | 5 |
0.021 | 555000 | 2 |
0.022 | 997769 | 4 |
0.023 | 1449422 | 4 |
0.024 | 153949 | 2 |
Last trade - 15.59pm 04/10/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |